Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 6/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.38 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2932279 | 0.90 | KCNH2 (0.37) | MTORPIK3CDPIK3CBTBK1 | |
| SCHEMBL2927230 | 0.83 | PIK3CA (0.39) | PIK3CAEGLN1MTORPIK3CDPIK3CB | |
| SCHEMBL2935297 | 0.81 | KCNH2 (0.35) | EGLN1MTORPIK3CDPIK3CBTBK1 | |
| SCHEMBL2930795 | 0.80 | PIK3CA (0.43) | PIK3CAMTORPIK3CDPIK3CBTBK1 | |
| SCHEMBL2931516 | 0.79 | KCNH2 (0.39) | PIK3CAEGLN1MTORPIK3CDPIK3CB | |
| SCHEMBL14693616 | 0.78 | PIK3CA (0.45) | PIK3CAMTORPIK3CDPIK3CBPKM | |
| SCHEMBL2924534 | 0.78 | KCNH2 (0.35) | EGLN1MTORPIK3CDPIK3CBTBK1 | |
| SCHEMBL14693584 | 0.77 | PIK3CA (0.48) | PIK3CAEGLN1MTORPIK3CDPIK3CB | |
| SCHEMBL2930096 | 0.77 | TBK1 (0.35) | TBK1 | |
| SCHEMBL2925852 | 0.76 | DRD3 (0.37) | MTORPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377983-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-7820821-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | VTVX HOLDINGS I LLC | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | AURKC, AURKA, AURKB | PIK3CA 21/4885EGLN1 2296/4885MTOR 533/4885 |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | AURKC, AURKA, AURKB | PIK3CA 21/4885EGLN1 2296/4885MTOR 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.